BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Sho T, Morikawa K, Kubo A, Tokuchi Y, Kitagataya T, Yamada R, Shigesawa T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Sakamoto N. Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy. World J Gastrointest Oncol 2021; 13(12): 2076-2087 [PMID: 35070043 DOI: 10.4251/wjgo.v13.i12.2076]
URL: https://www.wjgnet.com/1948-5204/full/v13/i12/2076.htm
Number Citing Articles
1
Paula Fernández-Palanca, Tania Payo-Serafín, Beatriz San-Miguel, Carolina Méndez-Blanco, María J. Tuñón, Javier González-Gallego, José L. Mauriz. Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradationActa Pharmacologica Sinica 2023; 44(5): 1066 doi: 10.1038/s41401-022-01021-2
2
Mara Persano, Andrea Casadei-Gardini, Valentina Burgio, Mario Scartozzi, Stefano Cascinu, Margherita Rimini. Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?Expert Review of Anticancer Therapy 2023; 23(1): 19 doi: 10.1080/14737140.2023.2156340
3
Yuta Tai, Yoshifumi Morita, Mitsumasa Makino, Shinya Ida, Ryuta Muraki, Ryo Kitajima, Makoto Takeda, Hirotoshi Kikuchi, Yoshihiro Hiramatsu, Hiroya Takeuchi. A Case of Giant Hepatocellular Carcinoma Successfully Treated with Lenvatinib Followed by Parenchymal-Sparing HepatectomyThe Japanese Journal of Gastroenterological Surgery 2023; 56(10): 547 doi: 10.5833/jjgs.2022.0104
4
Wenbin Liu, Zhiguo Xie, Kefeng Shen, Lizhu Jiang, Chongyan Liu, Yongsheng Ge, Jihai Yu, Weidong Jia, Jinliang Ma, Hao Chen. Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinomaMedical Oncology 2023; 40(9) doi: 10.1007/s12032-023-02082-x